Chimerix reported $814K in Gross Profit on Sales for its fourth fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Gross Profit On Sales Change
Ardelyx ARDX:US USD 41.02M 36.76M
Chimerix CMRX:US USD 814K 31.41M
Dynavax Technologies DVAX:US USD 107M 603K
Emergent Biosolutions EBS:US USD 111.3M 19.9M
Gilead Sciences GILD:US USD 5.99B 346M
Glaxosmithkline GSK:US GBP 5.2B 244M
Merk MRK:US USD 10.47B 610M
Novavax NVAX:US USD 175.63M 124.35M